

This correspondence is being deposited with the United States Postal Service as Express Mail EV 332107545 US in an envelope addressed to:

PATENT
Attorney Docket No.: 014058 013534

Box: Patent Application
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gaiger, et al.

Application No.: Not Assigned

Filed: January 23, 2004

For: INDUCTION OF BETA CELL
DIFFERENTIATION IN HUMAN
CELLS BY STIMULATION OF THE
GLP-1 RECEPTOR

Examiner: Not Assigned

Art Unit: Not Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached forms PTO/SB08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references on the PTO Forms SB08A and SB08B filed 10/21/02 can be found in Application No. **10/040,862**, filed 11/06/01 (Attorney Docket No. 014058-013520US). This application is a continuation of Application No. **10/040,862**. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and

no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Carol A. Fang
Reg. No. 48,631

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
MEH:jmm

60124765 v1


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

PATENT
Attorney Docket No.: 014058-013520US
Client Reference No.: CID 00494C1

On OCTOBER 21, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alexander GAIGER et al.

Application No.: 10/040,862

Filed: November 6, 2001

For: COMPOSITIONS AND METHODS
FOR THE DETECTION, DIAGNOSIS
AND THERAPY OF
HEMATOLOGICAL MALIGNANCIES

Examiner: To Be Assigned

Art Unit: 1645

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Reference nos. 2-3, 8-14, 19, and 23-25 are being submitted herewith. In accordance with 37 CFR §1.98(d), copies of reference nos. 1, 4-7, 15-18, and 20-22 can be found in Application No. 09/796,692, filed March 1, 2001 (Attorney Docket No. 014058-013512US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Peter Seperack
Reg. No. 47,932

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
PKS:ajg
SF 1398055 v1

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/040,862
				Filing Date	November 6, 2001
				First Named Inventor	Alexander GAIGER et. al.
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet 1		of 3	Attorney Docket Number 014058-013520US		

U.S. PATENT DOCUMENTS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US 5,342,761	08-30-1994	MacLeod	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)		
	2	PCT	WO 00/17222	A1	03-30-2000	
	3	PCT	WO 01/38490	A2	05-31-2001	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	4	Blomberg, B. "Homo sapiens IGLC Gene" DATABASE EMBL 'Online!': ID HSIGLC3A Acc. no. X06876, April 2, 1988.			
	5	Callanan, M.B., et al. "The IgG Fc Receptor, FcgammaRIIB, is a Target for Deregulation by Chromosomal Translocation in Malignant Lymphoma" DATABASE EMBL 'Online!': Acc. no. AF209720, January 19, 2000.			
	6	DATABASE EMBL 'Online!' "NCI, CGAP, Tumor Gene Index," Acc. no. AI141708, September 28, 1998.			
	7	DATABASE EMBL 'Online!' "NIH Mammalian Gene Collection," Acc. no. AW405794, February 8, 2000.			
	8	DAVIS, R.S. et al. "Identification of a family of Fc receptor homologs with preferential B cell expression," PNAS USA August 14, 2001, pp. 9772-9777, Vol. 98, No. 17.			
	9	DAVIS, R.S. et al. "Identification of a family of Fc receptor homologs with preferential B cell expression," NCBI Sequence Viewer: Acc. no. AY043464, September 8, 2001.			
	10	DAVIS, R.S. et al. "Identification of a family of Fc receptor homologs with preferential B cell expression," NCBI Sequence Viewer: Acc. no. AY043465, September 8, 2001.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1398055 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/040,862
				Filing Date	November 6, 2001
				First Named Inventor	Alexander GAIGER et. al.
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet 2		of 3	Attorney Docket Number 014058-013520US		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	11	DAVIS, R.S. et al. "Identification of a family of Fc receptor homologs with preferential B cell expression," NCBI Sequence Viewer: Acc. no. AY043466, September 8, 2001.		T ²
	12	DAVIS, R.S. et al. "Identification of a family of Fc receptor homologs with preferential B cell expression," NCBI Sequence Viewer: Acc. no. AF397452, August 22, 2001.		
	13	DAVIS, R.S. et al. "Identification of a family of Fc receptor homologs with preferential B cell expression," NCBI Sequence Viewer: Acc. no. AF397453, August 22, 2001.		
	14	HATZIVASSILIOU, G. et al. "IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy," <i>Immunity</i> March 2001, pp. 277-289, Vol. 14, No. 3.		
	15	Hillier, et al. "The WashU-Merck EST project" DATABASE EMBL 'Online!': Acc. no. R48079, May 24, 1995.		
	16	Hollis, et al. "Processed genes" DATABASE EMBL 'Online!': ID HSIGLAA Acc. no. K01326, June 13, 1985.		
	17	Klobbeck, H.G. "Human Rearranged Immunoglobulin Lambda Light Chain mRNA" DATABASE EMBL 'Online!': Acc. no. X57804, July 15, 1991.		
	18	Klobbeck, H.G. "Human Rearranged Immunoglobulin Lambda Light Chain mRNA" DATABASE EMBL 'Online!': Acc. no. X57820, July 15, 1991.		
	19	MILLER, I.J. et al. "IRTAs: a new family of immunoglobulin-like receptors differentially expressed in B cells," NCBI Sequence Viewer: Acc. no. AF459633, January 13, 2002.		
	20	Pilkington, et al. "Human clone rev16/20Fab" DATABASE EMBL 'Online!': Acc. no. L38562, January 7, 1995.		
	21	Simpson, A.J.G. "RC-6-HT0409-231299-011-A02" DATABASE EMBL 'Online!': Acc. no. AW384715, February 6, 2000.		
	22	Vasicek and Leder, "Human Myeloma U266 Cell Line" DATABASE EMBL 'Online!': Acc. no. AAQ22491, July 31, 1992.		
Examiner Signature		Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1398055 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete If Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/040,862
(use as many sheets as necessary)				Filing Date	November 6, 2001
				First Named Inventor	Alexander GAIGER et. al.
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet 3		of 3		Attorney Docket Number	014058-013520US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	23	XU, M. et al. "Molecular cloning and characterization of SPAP1, an inhibitory receptor," <i>Biochem. & Biophys. Res. Comm.</i> 2001, pp. 768-775, Vol. 280.		T ²
	24	XU, M.J. et al. "Molecular cloning and characterization of SPAP1, an inhibitory receptor," NCBI Sequence Viewer: Acc. no. AF319438, February 6, 2001.		
	25	XU, M.J. et al. "Molecular cloning and characterization of SPAP1, an inhibitory receptor," NCBI Sequence Viewer: Acc. no. AF319439, February 6, 2001.		

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1398055 v1